Vanguard Capital Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
Other funds holding FATE
Vanguard Capital Management's FATE Position: Q3 2026 in Review
Vanguard Capital Management increased its Fate Therapeutics (FATE) stake by 1.1% in Q3 2026, buying an estimated $131K and bringing the position to 4,496,086 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2718.
Vanguard Capital Management first reported a position in FATE in Q1 2026 and has held it in 3 quarters since. The position peaked at $12M in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.
- Vanguard Capital Management held 4,496,086 shares of Fate Therapeutics worth $10.7M as of Q3 2026.
- Vanguard Capital Management bought 50,550 Fate Therapeutics shares in Q3 2026, an estimated $131K.
- Fate Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2718 holding.
- Vanguard Capital Management first reported a position in Fate Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Fate Therapeutics position peaked at $12M in Q2 2026.
- 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.